Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | 57.60K | 112.10K | 235.10K | 232.90K | -478.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.60K | 112.10K | 235.10K | 232.90K | -478.60K |
| Cost of Revenue | 932.20K | 965.00K | 961.60K | 970.80K | -149.30K |
| Gross Profit | -874.60K | -852.80K | -726.40K | -737.70K | -329.20K |
| SG&A Expenses | 1.13M | 1.57M | 1.95M | 2.24M | 2.33M |
| Depreciation & Amortization | 451.40K | 469.40K | 437.40K | 504.00K | 535.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.59M | 3.14M | 3.50M | 3.88M | 2.87M |
| Operating Income | -2.53M | -3.02M | -3.27M | -3.65M | -3.35M |
| Income Before Tax | -2.57M | -2.59M | -2.80M | -2.92M | -3.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.57 | -2.59 | -2.80 | -2.92 | -3.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.57M | -2.59M | -2.80M | -2.92M | -3.65M |
| EBIT | -2.53M | -3.02M | -3.27M | -3.65M | -3.35M |
| EBITDA | -2.19M | -2.67M | -2.94M | -3.26M | -2.88M |
| EPS Basic | -0.07 | -0.07 | -0.07 | -0.08 | -0.10 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.04 | -0.04 | -0.06 |
| EPS Diluted | -0.07 | -0.07 | -0.07 | -0.08 | -0.10 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.04 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 155.56M | 154.38M | 152.80M | 151.04M | 147.82M |
| Average Diluted Shares Outstanding | 155.56M | 154.38M | 152.80M | 151.04M | 147.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |